Clinicopathological Significance of Expression of CD44 Variants in Head and Neck Squamous Cell Carcinoma

Kanke, Minoru; Fujisawa, Masato; Kameyama, Kaori; Kanzaki, Jin; Tokumaru, Yutaka; Imanishi, Yorihisa; Tomita, Toshiki; Matsumura, Yasuhiro

doi:10.1111/j.1349-7006.2000.tb00960.x

Cited by 12 publications

(8 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In previous studies, high expression frequencies exceeding 90% have been found in squamous cell carcinomas (SCCs) derived from head and neck, esophagus, skin and lung (10,(17)(18)(19)(20). Our studies are in agreement with those results.…”

Section: Discussionsupporting

confidence: 83%

Expression of CD44v6 is an independent prognostic factor for poor survival in patients with esophageal squamous cell carcinoma

et al. 2011

View full text Add to dashboard Cite

Abstract. CD44v6 has been causally associated with the development of metastases and with poor prognosis in various human malignancies. To elucidate the clinicopathological significance of CD44v6 expression in esophageal squamous cell carcinoma (ESCC), the present study aimed to investigate the expression of CD44v6 using immunohistological techniques. Using specific antibodies against CD44v6 and CD44s, expression of the proteins was analyzed immunohistochemically in 63 primary esophageal ESCCs, which were previously resected at the Nagoya City University Hospital without pre-operative induction therapy. Using light microscopy, the positive expression of CD44v6 was divided into a low-or highexpression group. The expression of CD44v6 in ESCC was analyzed with respect to various clinicopathological characteristics. The frequency of CD44v6 expression was 90.5% (57/63). The CD44v6 high-expression group comprised 55.6% of the patients (n=35) and the low expression group included 44.4% of the patients (n=28). In this study, no significant difference was observed between any clinicopathological factor and the immunohistochemical expression of CD44v6. In patients with high levels of CD44v6 expression, survival was markedly worse (p=0.0327). Favorable outcomes were observed for the clinicopathological characteristics of 6 patients whose tissue immunohistochemical expression of CD44v6 was not detected. Moreover, multivariate analysis confirmed that expression of CD44v6 was an independent prognostic indicator (risk ratio =2.793; p=0.0301). Overexpression of CD44v6 is a useful prognostic indicator of ESCC. Therefore, CD44v6 should be investigated as a potential target for therapy.

show abstract

Section: Discussionsupporting

confidence: 83%

Expression of CD44v6 is an independent prognostic factor for poor survival in patients with esophageal squamous cell carcinoma

et al. 2011

View full text Add to dashboard Cite

show abstract

“…(1998).,[ 12 ] Stoll et al .,[ 13 ] (1999), Kanke et al . (2000).,[ 14 ] Fonseca et al . (2001),[ 15 ] and Ue et al ., (2007).…”

Section: Discussionmentioning

confidence: 99%

Immunohistochemical study of CD44s expression in oral squamous cell carcinoma-its correlation with prognostic parameters

Hema

Rao

Devi

et al. 2014

J Oral Maxillofac Pathol

View full text Add to dashboard Cite

Background and Objectives:The study aims at the observation of the immunohistochemical expression of CD44s in Oral Squamous Cell Carcinoma (OSCC) and to correlate its expression with prognostic parameters.Materials and Methods:A total of 30 cases of OSCC, - 10 cases of each well differentiated (WD SCC), moderately differentiated (MD SCC) and poorly differentiated squamous cell carcinomas (PD SCC) were included in the study. The sections were subjected to immunohistochemical study using CD44s antigen marker. The degree of intensity and distribution of CD44s immunostaining was assessed and correlated with prognostic markers such as tumor stage (tumor size), tumor grade (Broder's histological grading), tumor site, tumor thickness (histological depth of invasion) and nodal status.Results:CD44s expression by tumor cells in OSCCs is statistically correlated with tumor grade i.e. Higher mean of CD44s immunoexpression was observed in WD SCC group (10.80 ± 3.97), followed by MD SCC group (5.90 ± 3.38) and PD SCC group showed least CD44s immunoexpression (3.70 ± 4.64). There was no statistical significance observed with respect to the other prognostic markers.Conclusion:Based on these observations it can be suggested that the decrease in expression of CD44s in OSCC cells may be due to the reduced cell-to-cell and cell-to-matrix adhesion, resulting in easy detachment from the rigid constitution. Low expression of CD44s in OSCC tissues may be an indicator of tumor invasion and high metastatic potential.

show abstract

“…However, others have reported that down‐regulation of various CD44 variant isoforms correlated with a worse prognosis. Kanke et al reported that down‐regulation of CD44 v2 correlated with poorer differentiation and shorter overall survival, while down‐regulation of CD44 v6 correlated with a higher rate of cervical metastasis 40, 41. Fonseca et al found down‐regulation of CD44 v3 and v6 correlated with tumor grade and pattern of invasion 7.…”

Section: Discussionmentioning

confidence: 99%

CD44 variant isoforms in head and neck squamous cell carcinoma progression

et al. 2009

View full text Add to dashboard Cite

OBJECTIVES/HYPOTHESIS The CD44 family of receptors includes multiple variant isoforms, several of which have been linked to malignant properties including migration, invasion, and metastasis. The objective of this study was to investigate the role of the CD44 v3, v6, and v10 variant isoforms in head and neck squamous cell carcinoma (HNSCC) tumor progression behaviors. STUDY DESIGN Laboratory study involving cell cultures and clinical tissue specimens. METHODS Analysis of the expression of standard CD44s and the CD44 variant isoforms v3, v6, and v10 was carried out in the HNSCC cell line, HSC-3. The role of CD44 isoforms in migration, proliferation, and cisplatin resistance was determined. Immunohistochemical analysis was performed on clinical tissue specimens obtained from a series of 82 HNSCC patients. The expression of standard CD44s and the CD44 v3, v6, and v10 variants in primary tumor specimens (n=82) and metastatic cervical lymph nodes (n=24) were analyzed with respect to various clinicopathologic variables. RESULTS HSC-3 cells express at least 4 CD44 isoforms, and these CD44 isoforms mediate migration, proliferation, and cisplatin sensitivity. Compared to primary tumors, a significantly greater proportion of metastatic lymph nodes demonstrated strong expression of CD44 v3 (lymph node: 14/24 vs. primary tumor: 38/82), CD44 v6 (lymph node: 18/24 vs. primary tumor: 26/82), and CD44 v10 (lymph node: 14/24 vs. primary tumor: 16/82), while expression of standard CD44 was not significantly different in metastatic lymph nodes and primary tumors (lymph node: 10/24 vs. primary tumor: 60/82). Expression of CD44 variant isoforms were associated with advanced T stage (v3 and v6), regional (v3) and distant (v10) metastasis, perineural invasion (v6), and radiation failure (v10). CD44 v6 and CD44 v10 were also significantly associated with shorter disease-free survival. CONCLUSION CD44 isoforms mediate migration, proliferation, and cisplatin sensitivity in HNSCC. Furthermore, expression of certain CD44 variants may be important molecular markers for HNSCC progression, and should be investigated as potential therapeutic targets for therapy.

show abstract

Clinicopathological Significance of Expression of CD44 Variants in Head and Neck Squamous Cell Carcinoma

Cited by 12 publications

References 33 publications

Expression of CD44v6 is an independent prognostic factor for poor survival in patients with esophageal squamous cell carcinoma

Expression of CD44v6 is an independent prognostic factor for poor survival in patients with esophageal squamous cell carcinoma

Immunohistochemical study of CD44s expression in oral squamous cell carcinoma-its correlation with prognostic parameters

CD44 variant isoforms in head and neck squamous cell carcinoma progression

Contact Info

Product

Resources

About